Loading…
Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma
Summary Aim : To evaluate adjuvant modalities after curative resection for hepatocellular carcinoma using a meta‐analysis of randomized and non‐randomized controlled trials. Methods : In a first step, a meta‐analysis of randomized controlled trials was carried out. Sensitivity analyses after inclusi...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 2003-05, Vol.17 (10), p.1247-1261 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5110-613817f2dd9a21e9e1dd093137b45ac04bfb3611107774660ad0f9c7dc3b7e0c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5110-613817f2dd9a21e9e1dd093137b45ac04bfb3611107774660ad0f9c7dc3b7e0c3 |
| container_end_page | 1261 |
| container_issue | 10 |
| container_start_page | 1247 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 17 |
| creator | Mathurin, P. Raynard, B. Dharancy, S. Kirzin, S. Fallik, D. Pruvot, F.‐R. Roumilhac, D. Canva, V. Paris, J.‐C. Chaput, J.‐C. Naveau, S. |
| description | Summary
Aim : To evaluate adjuvant modalities after curative resection for hepatocellular carcinoma using a meta‐analysis of randomized and non‐randomized controlled trials.
Methods : In a first step, a meta‐analysis of randomized controlled trials was carried out. Sensitivity analyses after inclusion of non‐randomized controlled trials were performed. Four therapeutic modalities were evaluated: pre‐operative transarterial chemotherapy, post‐operative transarterial chemotherapy, systemic chemotherapy and a combination of systemic and transarterial chemotherapy.
Results : Only post‐operative transarterial chemotherapy improved survival significantly at 2 years [difference, 22.8%; confidence interval (CI), 8.6–36.9%; P = 0.002] and 3 years (difference, 27.6%; CI, 8.2–47.1%; P = 0.005), and decreased the probability of no recurrence at 1 year (difference, 28.8%; CI, 16.7–40.8%; P |
| doi_str_mv | 10.1046/j.1365-2036.2003.01580.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73317440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73317440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5110-613817f2dd9a21e9e1dd093137b45ac04bfb3611107774660ad0f9c7dc3b7e0c3</originalsourceid><addsrcrecordid>eNqNkM1u1DAURi1ERYfCKyBvYJdwbSd2gsSiqviTitpFWVs3zrWawZMMdjLt7HgEnpEnadIZ0S2b6yv5fPanwxgXkAso9Pt1LpQuMwlK5xJA5SDKCvL7Z2z17-I5W4HUdSYroU7Zy5TWAKANyBfsVEhTlpWqVuzndxrx7-8_2GPYpy594LTDMOHYDT0fPMd2Pe2wH_l4SxG3e45-pMjdFGdkRzzMI_JIidxjxA-R39IWx8FRCFPAmcXoun7Y4Ct24jEken08z9iPz59uLr5ml1dfvl2cX2auFAIyLVQljJdtW6MUVJNoW6iVUKYpSnRQNL5RWsyoMabQGrAFXzvTOtUYAqfO2LvDu9s4_JoojXbTpaUO9jRMyRqlhCkKmMHqALo4pBTJ223sNhj3VoBdRNu1XXzaxaddRNtH0fZ-jr45_jE1G2qfgkezM_D2CGByGHzE3nXpiSsqWWutZ-7jgbvrAu3_u4A9v75ZNvUA7nKbxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73317440</pqid></control><display><type>article</type><title>Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma</title><source>Wiley</source><creator>Mathurin, P. ; Raynard, B. ; Dharancy, S. ; Kirzin, S. ; Fallik, D. ; Pruvot, F.‐R. ; Roumilhac, D. ; Canva, V. ; Paris, J.‐C. ; Chaput, J.‐C. ; Naveau, S.</creator><creatorcontrib>Mathurin, P. ; Raynard, B. ; Dharancy, S. ; Kirzin, S. ; Fallik, D. ; Pruvot, F.‐R. ; Roumilhac, D. ; Canva, V. ; Paris, J.‐C. ; Chaput, J.‐C. ; Naveau, S.</creatorcontrib><description>Summary
Aim : To evaluate adjuvant modalities after curative resection for hepatocellular carcinoma using a meta‐analysis of randomized and non‐randomized controlled trials.
Methods : In a first step, a meta‐analysis of randomized controlled trials was carried out. Sensitivity analyses after inclusion of non‐randomized controlled trials were performed. Four therapeutic modalities were evaluated: pre‐operative transarterial chemotherapy, post‐operative transarterial chemotherapy, systemic chemotherapy and a combination of systemic and transarterial chemotherapy.
Results : Only post‐operative transarterial chemotherapy improved survival significantly at 2 years [difference, 22.8%; confidence interval (CI), 8.6–36.9%; P = 0.002] and 3 years (difference, 27.6%; CI, 8.2–47.1%; P = 0.005), and decreased the probability of no recurrence at 1 year (difference, 28.8%; CI, 16.7–40.8%; P < 0.001), 2 years (difference, 27.6%; CI, 8.2–47.1%; P = 0.005) and 3 years (difference, 28%; CI, 8.2–47.9%; P = 0.006). In a sensitivity analysis after inclusion of non‐randomized controlled trials, post‐operative transarterial chemotherapy still improved survival at 1 year (difference, 9.6%; CI, 0.8–18.3%; P = 0.03), 2 years (difference, 13.5%; CI, 0.9–26%, P = 0.04) and 3 years (difference, 18%; CI, 7–28.9%; P < 0.001), and decreased the probability of no recurrence at 1 year (difference, 20.3%; CI, 7.7–33%; P = 0.002), 2 years (difference, 35%; CI, 21.4–46.3%; P < 0.001) and 3 years (difference, 34.5%; CI, 18.7–50.3%; P < 0.001).
Conclusion : Post‐operative transarterial chemotherapy improved survival and decreased the cumulative probability of no recurrence. New randomized controlled trials evaluating this modality are required.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.2003.01580.x</identifier><identifier>PMID: 12755838</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - surgery ; Chemotherapy, Adjuvant ; Controlled Clinical Trials as Topic ; Drug Therapy, Combination ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - surgery ; Medical sciences ; Neoplasm Recurrence, Local - etiology ; Postoperative Care ; Preoperative Care ; Randomized Controlled Trials as Topic ; Survival Analysis ; Treatment Outcome</subject><ispartof>Alimentary pharmacology & therapeutics, 2003-05, Vol.17 (10), p.1247-1261</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5110-613817f2dd9a21e9e1dd093137b45ac04bfb3611107774660ad0f9c7dc3b7e0c3</citedby><cites>FETCH-LOGICAL-c5110-613817f2dd9a21e9e1dd093137b45ac04bfb3611107774660ad0f9c7dc3b7e0c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14829666$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12755838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mathurin, P.</creatorcontrib><creatorcontrib>Raynard, B.</creatorcontrib><creatorcontrib>Dharancy, S.</creatorcontrib><creatorcontrib>Kirzin, S.</creatorcontrib><creatorcontrib>Fallik, D.</creatorcontrib><creatorcontrib>Pruvot, F.‐R.</creatorcontrib><creatorcontrib>Roumilhac, D.</creatorcontrib><creatorcontrib>Canva, V.</creatorcontrib><creatorcontrib>Paris, J.‐C.</creatorcontrib><creatorcontrib>Chaput, J.‐C.</creatorcontrib><creatorcontrib>Naveau, S.</creatorcontrib><title>Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Aim : To evaluate adjuvant modalities after curative resection for hepatocellular carcinoma using a meta‐analysis of randomized and non‐randomized controlled trials.
Methods : In a first step, a meta‐analysis of randomized controlled trials was carried out. Sensitivity analyses after inclusion of non‐randomized controlled trials were performed. Four therapeutic modalities were evaluated: pre‐operative transarterial chemotherapy, post‐operative transarterial chemotherapy, systemic chemotherapy and a combination of systemic and transarterial chemotherapy.
Results : Only post‐operative transarterial chemotherapy improved survival significantly at 2 years [difference, 22.8%; confidence interval (CI), 8.6–36.9%; P = 0.002] and 3 years (difference, 27.6%; CI, 8.2–47.1%; P = 0.005), and decreased the probability of no recurrence at 1 year (difference, 28.8%; CI, 16.7–40.8%; P < 0.001), 2 years (difference, 27.6%; CI, 8.2–47.1%; P = 0.005) and 3 years (difference, 28%; CI, 8.2–47.9%; P = 0.006). In a sensitivity analysis after inclusion of non‐randomized controlled trials, post‐operative transarterial chemotherapy still improved survival at 1 year (difference, 9.6%; CI, 0.8–18.3%; P = 0.03), 2 years (difference, 13.5%; CI, 0.9–26%, P = 0.04) and 3 years (difference, 18%; CI, 7–28.9%; P < 0.001), and decreased the probability of no recurrence at 1 year (difference, 20.3%; CI, 7.7–33%; P = 0.002), 2 years (difference, 35%; CI, 21.4–46.3%; P < 0.001) and 3 years (difference, 34.5%; CI, 18.7–50.3%; P < 0.001).
Conclusion : Post‐operative transarterial chemotherapy improved survival and decreased the cumulative probability of no recurrence. New randomized controlled trials evaluating this modality are required.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Chemotherapy, Adjuvant</subject><subject>Controlled Clinical Trials as Topic</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - surgery</subject><subject>Medical sciences</subject><subject>Neoplasm Recurrence, Local - etiology</subject><subject>Postoperative Care</subject><subject>Preoperative Care</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqNkM1u1DAURi1ERYfCKyBvYJdwbSd2gsSiqviTitpFWVs3zrWawZMMdjLt7HgEnpEnadIZ0S2b6yv5fPanwxgXkAso9Pt1LpQuMwlK5xJA5SDKCvL7Z2z17-I5W4HUdSYroU7Zy5TWAKANyBfsVEhTlpWqVuzndxrx7-8_2GPYpy594LTDMOHYDT0fPMd2Pe2wH_l4SxG3e45-pMjdFGdkRzzMI_JIidxjxA-R39IWx8FRCFPAmcXoun7Y4Ct24jEken08z9iPz59uLr5ml1dfvl2cX2auFAIyLVQljJdtW6MUVJNoW6iVUKYpSnRQNL5RWsyoMabQGrAFXzvTOtUYAqfO2LvDu9s4_JoojXbTpaUO9jRMyRqlhCkKmMHqALo4pBTJ223sNhj3VoBdRNu1XXzaxaddRNtH0fZ-jr45_jE1G2qfgkezM_D2CGByGHzE3nXpiSsqWWutZ-7jgbvrAu3_u4A9v75ZNvUA7nKbxQ</recordid><startdate>20030515</startdate><enddate>20030515</enddate><creator>Mathurin, P.</creator><creator>Raynard, B.</creator><creator>Dharancy, S.</creator><creator>Kirzin, S.</creator><creator>Fallik, D.</creator><creator>Pruvot, F.‐R.</creator><creator>Roumilhac, D.</creator><creator>Canva, V.</creator><creator>Paris, J.‐C.</creator><creator>Chaput, J.‐C.</creator><creator>Naveau, S.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030515</creationdate><title>Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma</title><author>Mathurin, P. ; Raynard, B. ; Dharancy, S. ; Kirzin, S. ; Fallik, D. ; Pruvot, F.‐R. ; Roumilhac, D. ; Canva, V. ; Paris, J.‐C. ; Chaput, J.‐C. ; Naveau, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5110-613817f2dd9a21e9e1dd093137b45ac04bfb3611107774660ad0f9c7dc3b7e0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Chemotherapy, Adjuvant</topic><topic>Controlled Clinical Trials as Topic</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - surgery</topic><topic>Medical sciences</topic><topic>Neoplasm Recurrence, Local - etiology</topic><topic>Postoperative Care</topic><topic>Preoperative Care</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mathurin, P.</creatorcontrib><creatorcontrib>Raynard, B.</creatorcontrib><creatorcontrib>Dharancy, S.</creatorcontrib><creatorcontrib>Kirzin, S.</creatorcontrib><creatorcontrib>Fallik, D.</creatorcontrib><creatorcontrib>Pruvot, F.‐R.</creatorcontrib><creatorcontrib>Roumilhac, D.</creatorcontrib><creatorcontrib>Canva, V.</creatorcontrib><creatorcontrib>Paris, J.‐C.</creatorcontrib><creatorcontrib>Chaput, J.‐C.</creatorcontrib><creatorcontrib>Naveau, S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mathurin, P.</au><au>Raynard, B.</au><au>Dharancy, S.</au><au>Kirzin, S.</au><au>Fallik, D.</au><au>Pruvot, F.‐R.</au><au>Roumilhac, D.</au><au>Canva, V.</au><au>Paris, J.‐C.</au><au>Chaput, J.‐C.</au><au>Naveau, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2003-05-15</date><risdate>2003</risdate><volume>17</volume><issue>10</issue><spage>1247</spage><epage>1261</epage><pages>1247-1261</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Aim : To evaluate adjuvant modalities after curative resection for hepatocellular carcinoma using a meta‐analysis of randomized and non‐randomized controlled trials.
Methods : In a first step, a meta‐analysis of randomized controlled trials was carried out. Sensitivity analyses after inclusion of non‐randomized controlled trials were performed. Four therapeutic modalities were evaluated: pre‐operative transarterial chemotherapy, post‐operative transarterial chemotherapy, systemic chemotherapy and a combination of systemic and transarterial chemotherapy.
Results : Only post‐operative transarterial chemotherapy improved survival significantly at 2 years [difference, 22.8%; confidence interval (CI), 8.6–36.9%; P = 0.002] and 3 years (difference, 27.6%; CI, 8.2–47.1%; P = 0.005), and decreased the probability of no recurrence at 1 year (difference, 28.8%; CI, 16.7–40.8%; P < 0.001), 2 years (difference, 27.6%; CI, 8.2–47.1%; P = 0.005) and 3 years (difference, 28%; CI, 8.2–47.9%; P = 0.006). In a sensitivity analysis after inclusion of non‐randomized controlled trials, post‐operative transarterial chemotherapy still improved survival at 1 year (difference, 9.6%; CI, 0.8–18.3%; P = 0.03), 2 years (difference, 13.5%; CI, 0.9–26%, P = 0.04) and 3 years (difference, 18%; CI, 7–28.9%; P < 0.001), and decreased the probability of no recurrence at 1 year (difference, 20.3%; CI, 7.7–33%; P = 0.002), 2 years (difference, 35%; CI, 21.4–46.3%; P < 0.001) and 3 years (difference, 34.5%; CI, 18.7–50.3%; P < 0.001).
Conclusion : Post‐operative transarterial chemotherapy improved survival and decreased the cumulative probability of no recurrence. New randomized controlled trials evaluating this modality are required.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>12755838</pmid><doi>10.1046/j.1365-2036.2003.01580.x</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2003-05, Vol.17 (10), p.1247-1261 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73317440 |
| source | Wiley |
| subjects | Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - surgery Chemotherapy, Adjuvant Controlled Clinical Trials as Topic Drug Therapy, Combination Humans Liver Neoplasms - drug therapy Liver Neoplasms - surgery Medical sciences Neoplasm Recurrence, Local - etiology Postoperative Care Preoperative Care Randomized Controlled Trials as Topic Survival Analysis Treatment Outcome |
| title | Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T17%3A45%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Meta%E2%80%90analysis:%20evaluation%20of%20adjuvant%20therapy%20after%20curative%20liver%20resection%20for%20hepatocellular%20carcinoma&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Mathurin,%20P.&rft.date=2003-05-15&rft.volume=17&rft.issue=10&rft.spage=1247&rft.epage=1261&rft.pages=1247-1261&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.2003.01580.x&rft_dat=%3Cproquest_cross%3E73317440%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5110-613817f2dd9a21e9e1dd093137b45ac04bfb3611107774660ad0f9c7dc3b7e0c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73317440&rft_id=info:pmid/12755838&rfr_iscdi=true |